Giredestrant and Everolimus

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer

Roche plans regulatory engagement after ESMO 2025 results showed the clearest gains in ESR1‑mutated tumors.